Page 122 - The diagnostic work-up of women with postmenopausal bleeding

Chapter 6
Figure 3b. Cost-effectiveness acceptability curve for number of women with recurrent bleeding during 12 months of follow-up
The ICER for detected carcinoma shows that to detect one case of (pre) cancer € 10,917 should be invested in the hysteroscopy group as compared with the expectant management group (Table 3).The CE plane in Figure 4a shows that there is some uncertainty around the ICER, but confirms the statistically significant effect difference (bootstrapped cost-effect pairs distributed across the eastern quadrants of the plane) and the statistically significant cost difference (all bootstrapped cost- effect pairs located in the northern quadrants of the plane).The CEA curve (Figure 4b) shows that at willingness-to-pay values of € 5,000 or 10,000 or 20,000/detected (pre) cancer extra the probability that the intervention is cost-effective in comparison with usual care is 0, 0.31 and 0.96, respectively. At a willingness to pay of 19,500 € / detected (pre) cancer extra, the probability of cost-effectiveness is 0.95.
120